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Background: Women with hyper-and hypothyroidism are at increased risk for infertility and adverse pregnancy
outcomes. Whether in women considered euthyroid thyroid function (TSH values) and thyroid autoimmunity (thyroid
antibodies) influence in vitro fertilization (IVF) cycle outcome has, however, remained controversial. Any such
effect should be easily visible in women with low functional ovarian reserve (LFOR) and thus small oocyte and
embryo numbers.
Methods: We evaluated the relationship between TSH levels and embryo quality in euthyroid women with LFOR
undergoing IVF. Mean age for the study population was 39.9 ± 4.6 years. Embryo quality was assessed in 431
embryos from 98 first IVF cycles according to TSH levels (with cut-off 2.5μIU/mL), and to presence versus absence
of thyroid autoantibodies.
Results: Mean Anti Mullerian hormone (AMH) was 0.8 ± 0.8 ng/mL and mean TSH was 1.8 ± 0.9 μIU/mL. Comparable
embryo quality was observed in women with TSH≤ and >2.5μIU/mL. TPO antibodies significantly affected embryo
quality in women with low-normal TSH levels (P = 0.045). In women with high-normal TSH levels, increasing TSH had a
negative impact on embryo quality (P = 0.027). A trend towards impaired embryo quality with TPO antibodies was also
observed in these patients (p = 0.057).
Conclusions: TPO antibodies affect embryo quality in euthyroid women with low-normal TSH ≤2.5 μIU/mL. In women
with high-normal TSH levels, increasing TSH levels, and possibly TPO antibodies, appear to impair embryo quality. These
results suggest that the negative impact of thyroid autoimmunity becomes apparent, once thyroid hormone function
is optimized.
Keywords: Diminished Ovarian Reserve (DOR), Embryo quality, Euthyroid, In Vitro Fertilization (IVF), Low Functional
Ovarian Reserve (LFOR), Thyroid autoimmunity, Thyroid Stimulating Hormone (TSH)Background
Thyroid dysfunction is the most common endocrine disorder
in women of reproductive years [1–3]. Hypothyroidism
may cause menstrual irregularities and is believed to in-
crease miscarriage rates [4–6].* Correspondence: andrea.weghofer@meduniwien.ac.at
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unless otherwise stated.Thyroid function and female reproduction are closely
related. This relationship appears especially pronounced
during pregnancy and in women who undergo fertility
treatment: Once estrogen serum concentrations rise
above physiological thresholds, thyroid-binding globulin
levels increase. Thyroid-binding globulin binds thyroxin
and leaves less free thyroid hormone available. Then
thyroid-stimulating hormone (TSH) rises to ensure suffi-
cient thyroid hormone supply [7, 8].
These observations led to the suspicion that thyroid
function may influence in vitro fertilization (IVF) cycleral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and/or thyroid autoimmunity affect female fertility and
pregnancy potential in spontaneous and/or IVF cycles has
remained subject of substantial disagreement [9–11].
Busnelli et al. recently demonstrated comparable im-
plantation and live birth rates in IVF patients with clin-
ical and subclinical hypothyroidism under levothyroxin
treatment, and in presence and absence of thyroid auto-
immunity [12]. Similarly, Chai et al. described compar-
able IVF pregnancy rates in women with normal TSH
levels with thyroid autoimmunity and/or subclinical
hypothyroidism [13].
Scoccia et al., in contrast, reported significantly lower
implantation and pregnancy rates in women with supple-
mented hypothyroidism undergoing assisted reproduction
when compared to controls [8]. Monteleone et al. are in
accordance with these findings. They reported lower
fertilization and pregnancy rates in patients with thyroid
autoimmunity when compared to controls [14].
Whether thyroid function and/or thyroid autoimmun-
ity affect embryo quality has not yet been investigated. If
thyroid function and/or thyroid autoimmunity affect em-
bryo quality, such an effect would be especially apparent
in women with low functional ovarian reserve (LFOR),
who produce limited oocyte numbers during IVF.
To investigate the effects of thyroid function and thyroid
autoimmunity on embryo quality in IVF patients with low
functional ovarian reserve, the present study was initiated.Methods
Patients
This study investigated 431 embryos in 98 infertility
patients, who all underwent their first IVF cycles between
January 2011 and February 2013 at the Center for Human
Reproduction (CHR) in New York City.
Routine pre-IVF evaluation at the center includes ovar-
ian function determinations by baseline follicle stimu-
lating hormone (FSH) on cycle days 2/3 and random
anti-Müllerian hormone (AMH), TSH and thyroid auto-
antibody assessments for thyroid peroxidase (TPO), anti-
thyroglobulin (TG) and thyroid receptor antibodies (TR),
and prolactin levels. All hormone assessments were made
by routine commercial assays.
Only women with normal thyroid function (i.e., TSH
levels 0.45–4.5 μIU/mL) and normal serum prolactin
were eligible for enrollment. Moreover, patients had to
suffer from low functional ovarian reserve. A diagnosis
of LFOR was established if women presented with ab-
normally elevated age-specific baseline FSH and/or ab-
normally low age-specific AMH. Normal age-specific
hormone levels were defined as previously reported [15,
16]. Thyroid antibody status was considered positive in
the presence of one or more thyroid antibodies.Laboratory assays
FSH, TSH and prolactin levels as well as TPO and TR
antibodies were assessed by electrochemiluminescence
immunoassay (ECLIA). AMH levels were measured by
electrochemiluminescence (ECL). An immunochemilumi-
nometric assay (ICMA) was utilized for anti-thyroglobulin
and anti-thyrotropin receptor antibody measurements.IVF procedure
Since all here investigated patients suffered from LFOR,
their ovarian stimulation was uniform, and included
microdose GnRH agonist treatment (leuprolide acetate,
Lupron®, Abbott Laboratories, North Chicago, Illinois)
in 88.8 % of cycles. GnRH antagonist was applied in
11.2 % of cycles, usually only after patients had broken
through with premature ovulation in a prior agonist
cycle.
Ovarian stimulation routinely involved, as previously
reported, FSH preponderance (300–450 I.U.) and a
smaller dosage of daily human menopausal gonadotropin
(hMG, 150 I.U.), with gonadotropin manufacturers de-
pending on patient preference and insurance coverage
[17]. When at least one follicle at 18–20 mm diameter
was present, ovulation was induced with 10,000 I.U. of
urinary human chorionic gonadotrophin (u-hCG).
After oocyte retrieval, oocytes are routinely incubated
for at least 2 hours in an organ dish containing human
tubal fluid (HTF) media (LifeGlobal, LLC, Gilford, CT)
supplemented with 10 % human serum albumin (HSA,
LifeGlobal, LLC, Gilford, CT). Then oocytes are stripped
of cumulus cells with 80 IU/ml hyaluronydase (LifeGlobal,
LLC, Gilford, CT) and by mechanically denudation.
Intracytoplasmic sperm injection (ICSI) is only per-
formed on mature oocytes. Oocytes are placed into an
ICSI dish containing 25 ul drops of HTF with HEPES,
with 10 % of HSA added under mineral oil (LifeGlobal,
LLC, Gilford, CT). Each drop is labeled. Following ICSI,
oocytes are cultured individually under mineral oil in la-
beled drops (100 ul) of blastocyst media (LifeGlobal,
LLC, Gilford, CT), supplemented with 10 % HSA. Dishes
are prepared on the day prior to oocyte retrieval.
Quality of mature oocytes is documented by photog-
raphy (INFINITY software, Lumenera Corp, Ottawa,
Contario, Canada) prior to sperm injection and assessed
during ICSI by the embryologist. Each oocyte is placed
into a single-numbered drop in an ICSI dish, allowing
for longitudinal assessments of subsequent fertilization
and embryo development.
Microscopic evaluation of fertilization (or lack thereof )
was performed approximately 18 h after ICSI. Zygotes
were then incubated uninterrupted until day-3. On day-
3 each embryo was individually evaluated by assessing
blastomere numbers, embryo shape and fragmentation.
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Embryo quality was assessed in a total of 431 embryos.
Embryos were considered of good quality if they reached
4-cell stage on day 2 after fertilization and 8-cell stage with
Grades 4 or 5 on day 3. They were considered of poor
quality if they arrested, degenerated or only reached Grade
2; and they were considered fair if they fell in-between the
first two groups [18]. Embryos of good quality were coded
as 1, those of fair quality were coded as 2 and poor quality
embryos were coded as 3. Due to limited embryo numbers
in our center’s highly adversely selected patient popula-
tion, embryo transfer is usually performed on day-3.
Statistics
Thyroid function was measured by thyroid-stimulating
hormone (TSH) levels. Thyroid autoimmunity was mea-
sured by the presence of at least one positive thyroid anti-
body test. Normal thyroid function was divided into low-
normal and high-normal TSH levels with a cut-off of
2.5 μIU. This cutoff was previously reported by Busnelli
et al. to distinguish between low-normal and high-normal
TSH [9]. TSH levels were analyzed as continuous and as
categorical variables. Embryo quality was measured as ei-
ther poor, fair or good. Female age and oocyte numbers
were determined as potential confounding factors.
A cumulative logit model was used while embryos were
clustered by patient. All models passed the Pearson’s chi-
squared goodness of fit test with non-significant p-values.
Univariate analysis determined significant predictors
which were then used in multivariate analysis. Pearson’s
correlations with p-values are shown in Table 2.
Subgroup analyses were performed for the low-normal
and the high-normal TSH groups Univariate analysis de-
termined significant predictors which were then used in
multivariate analysis (Table 3).
A 20 % difference in embryo quality between women
with TSH ≤ 2.5 μIU/mL and those with TSH > 2.5 μIU/
mL was estimated to be clinically significant. A power
analysis was performed to calculate the number of em-
bryos required per group to detect such a difference. To
reach sufficient statistical power, 93 embryos per TSH
group were required. The here presented study, there-
fore, clearly was of adequate size to detect such a 20 %
difference in embryo quality.
Pregnancy and live birth rates were also assessed and
reported, but not included in regression analyses, as case
numbers were too small to draw valid conclusions.
Analyses were conducted using SPSS version 22.
Covariates were considered statistically significant at P-
values <0.05.
Institutional review board
Here presented data only involved retrospective review of
medical records and data from a de-identified researchdatabase. Patients at our center sign an informed consent
at initial consultation, which allows for such reviews if the
patient’s medical record remains confidential and her
identity protected. These conditions were met in this case,
allowing for expedited approval by the Institutional Re-
view Board of The Center for Human Reproduction, NY,
New York.Results
Patient and cycle characteristics are presented in Table 1.
Mean age of all investigated patients was 39.6 ± 4.6 years,
mean FSH was 11.4 ± 6.6 IU/mL, mean AMH 0.8 ±
0.8 ng/mL and mean TSH 1.8 ± 0.9 μIU/mL.
Seventy-seven women (77.8 %) presented with TSH
levels ≤2.5 μIU/mL and 21 (21.2 %) with TSH above
2.5 μIU/mL. Thyroid autoimmunity was present in 17
patients (17.3 %). Thyroid autoimmunity and TPO posi-
tive antibody status occurred more often in women with
high normal TSH levels (P = 0.015 and P = 0.003, re-
spectively). Mean thyroid peroxidase antibody values
were 411.3 ± 769.5 IU/mL, mean thyroglobulin antibody
levels were 146.4 ± 122.2 IU/mL and mean thyroid re-
ceptor antibody levels were 3.2 ± 0.8 IU/L. Mean prolac-
tin levels were 12.7 ± 5.9 ng/mL.
After ovarian stimulation, a mean number of 6.7 ± 4.4
oocytes were retrieved. Among a total of 431 embryos,
203 (47.1 %) were classified as good, 183 (42.5 %) as fair
and 45 (10.4 %) as poor quality embryos.
Embryo quality was not statistically different between
TSH classifications of low-normal and high-normal TSH
levels (Table 2, Fig. 1). Embryo quality correlated with
oocyte numbers (R = −0.101;P = 0.036). A trend toward
impaired embryo quality in the presence of thyroid auto-
immunity was observed (P = 0.052). This trend was
mainly attributable to the presence of TPO antibodies
(P = 0.051). Multivariate regression, corrected for age
and oocyte numbers, showed no significant correlation
between embryo quality and TSH function and thyroid
autoimmunity, respectively (Table 3).
Then potential impacts of thyroid function and thy-
roid autoimmunity on embryo quality were investigated
among the low-normal and high-normal TSH sub-
groups. In women with low-normal TSH levels, female
age (P = 0.012), oocyte numbers (P = 0.034), thyroid auto-
immunity (P = 0.030) and TPO antibodies (P = 0.021) sig-
nificantly affected embryo quality in univariate regression
analysis. TPO antibody status significantly influenced em-
bryo quality, when controlled for age and oocyte numbers
(P = 0.045).
In women with high-normal TSH levels, increasing
TSH levels were associated with impaired embryo qual-
ity (P = 0.013). This association remained significant in
multiregression analysis. Additionally, a trend towards
Table 1 Patient and IVF cycle characteristics of 98 euthyroid women suffering from diminished ovarian function and their 431
embryos according to TSH levels
All TSH ≤2.5μIU/mL TSH >2.5μIU/mL
(n = 98/431) (n = 77/330) (n = 21/101)
Female age (years) 39.6 ± 4.6 39.8 ± 4.5 38.8 ± 5.1
Baseline FSH (IU/mL) 11.4 ± 6.6 11.6 ± 6.9 10.5 ± 5.2
AMH (ng/mL) 0.8 ± 0.8 0.8 ± 0.8 0.8 ± 0.7
TSH (μIU/mL) 1.8 ± 0.9 1.5 ± 0.5 3.1 ± 0.4
Thyroid autoimmunity (%) 17.3 % 11.7 %* 38.1 %*
Thyroid peroxidase antibodies (%) 13.3 % 9.1 %** 28.6 %**
Thyroglubulin antibodies (%) 9.2 % 7.8 % 14.3 %
Thyroid receptor antibodies (%) 2.0 % 2.6 % 4.8 %
Total gonadotrophin dosage (IU) 6593.6 ± 2579.7 6613.3 ± 2599.2 6521.4 ± 2568.3
Number of oocytes retrieved 6.7 ± 4.4 6.7 ± 4.5 7.1 ± 3.7
Number of embryos transferred 2.6 ± 1.0 2.5 ± 1.0 2.7 ± 1.1
Good quality embryos (n, %) 203 (47.1 %) 152 (46.1 %) 51 (50.5 %)
Fair quality embryos (n, %) 183 (42.5 %) 141 (42.7 %) 42 (41.6 %)
Poor quality embryos (n, %) 45 (10.4 %) 37 (11.2 %) 8 (7.9 %)
Clinical pregnancy rate (%) 20.7 % 22.2 % 15.0 %
Live birth rate (%) 13.0 % 13.9 % 5.0 %
Values are presented as means ± SD
More than one thyroid antibody may be present in women with thyroid autoimmunity. Thus, percentages of the various thyroid antibodies may not add up to 100 %.
Baseline and cycle characteristics are not statistically different between groups, if not indicated
*P = 0.015,**P = 0.003
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was observed (P = 0.056).
Among study participants, embryo transfer was per-
formed in 93.9 % of women with a mean number of 2.6 ±
1.0 embryos transferred. The remaining patient cycles ei-
ther demonstrated embryonic arrest or were eligible for
embryo banking. The clinical pregnancy per transfer was
20.7 %, live birth rate was 13.0 %. Due to the small num-
ber of pregnancies, statistical analysis on the impact of
baseline TSH levels on pregnancy potential was notFig. 1 Embryo quality in references to TSH levels in 431 embryos
from 98 first IVF cycles in 98 euthyroid women with low functional
ovarian reservefeasible. However, a trend towards improved pregnancy
potential in the presence of low-normal TSH levels (i.e.
TSH ≤ 2.5 μIU/mL) was observed.
Discussion
This study demonstrates comparable embryo quality in
women with low-normal and high-normal TSH levels.
Our results are in accordance with Reh et al., who re-
port comparable pregnancy, delivery and miscarriage
rates among IVF patients with a TSH cut off of 2.5 μIU/
mL [19]. These findings allow for different interpreta-
tions: One may assume that TSH levels within normal
ranges have consistent effects on embryo quality [19].
Alternatively, one may speculate that the TSH cut off of
2.5 μIU/mL may be too low. Our data seem to support
such an assumption: In women with high normal TSH
levels, TSH increase was associated with poorer embryo
quality. Such an assumption may also explain the con-
flicting results observed in the literature [9–12].
One may also assume that thyroid autoimmunity, ra-
ther than thyroid hormone concentrations, may impair
IVF cycle outcomes [8]. Our findings appear to demon-
strate such an effect: It appears that most of thyroid
autoimmunity effect was due to positive TPO antibody
status. Indeed, TPO antibodies significantly affected em-
bryo quality in euthyroid women with low-normal TSH
levels. The same trend was observed in women with
Table 2 Pearson’s correlation of embryo quality with thyroid
function and autoimmunity in 98 euthyroid women suffering
from diminished ovarian function
R p
All TSH levels
Age (years) 0.07096 0.1414
Number of oocytes −0.10111 0.0359
TSH (μIU/mL) 0.02186 0.6509
TSH-cutoff (2.5μIU/mL) −0.04928 0.3074
Thyroid autoimmunity −0.09462 0.0515
TPO antibody status 0.09513 0.0508
TG antibody status −0.01567 0.7491
Low-normal TSH levels (TSH ≤ 2.5μIU/mL)
Age (years) 0.13800 0.0121
Number of oocytes −0.11697 0.0337
TSH (μIU/mL) 0.07326 0.1844
Thyroid autoimmunity −0.12046 0.0302
TPO antibody status 0.12856 0.0210
TG antibody status −0.05218 0.3529
High-normal TSH levels (TSH > 2.5μIU/mL)
Age (years) −0.16302 0.1033
Number of oocytes −0.06275 0.5331
TSH (μIU/mL) 0.24719 0.0127
Thyroid autoimmunity 0.00641 0.9495
TPO antibody status 0.07138 0.4803
TG antibody status 0.10443 0.3011
Table 3 Mulitvariate analysis of the impact of thyroid function




TSH (μIU/mL) 0.0130 0.8159
Thyroid autoimmunity 0.0189 0.1509
TPO antibody status 0.0119 0.1141
TG antibody status 0.0142 0.8835
Low-normal TSH Levels (TSH ≤ 2.5μIU/mL)
TSH (μIU/mL) 0.0301 0.2664
Thyroid autoimmunity 0.0330 0.2950
TPO antibody status 0.0404 0.0454
TG antibody status 0.0306 0.6836
High-normal TSH levels (TSH > 2.5μIU/mL)
TSH (μIU/mL) 0.0782 0.0266
Thyroid autoimmunity 0.0548 0.1146
TPO antibody status 0.0663 0.0557
TG antibody status 0.0405 0.3053
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tions to further elucidate the clinical significance of our
findings.
That infertile women demonstrate a higher prevalence
of autoimmunity than fertile controls [20, 21] further
supports a causal relationship between thyroid auto-
immune disease and impaired IVF cycle outcomes. Ma-
ternal tolerance needs to be established to facilitate
embryonic implantation and autoimmunity appears to
hinder this process [22]. It is tempting to speculate that
embryo quality and implantation may be impaired in
women with thyroid autoimmunity.
Higher miscarriage rates have also been reported in
euthyroid women with signs of thyroid autoimmunity
[14]. An effect that aligns well with impaired embryo
quality we observed in the presence of TPO antibodies.
A recent meta-analysis by Velkeniers et al. concluded
that thyroxine treatment in women with subclinical
hypothyroidism and/or thyroid autoimmunity improves
fertilization, implantation and live birth rate in women
undergoing assisted reproduction. Additionally, significant
decreases in miscarriage risk were reported. Women
with thyroid autoimmunity in association with IVF also
appear at increased risk of developing (sub-) clinical
hypothyroidism [21]. These results are in accordance with
our findings. Women with TSH > 2.5 μIU/mL levels
were more likely to demonstrate thyroid autoimmunity
(P = 0.015) and TPO antibodies (P = 0.003) than women
in the lower TSH group. We also observed decreasing
embryo quality with increasing TSH levels in patients
with high-normal TSH levels.
Conclusion
Our data demonstrate comparable embryo quality in
LFOR women with low-normal and high-normal TSH
levels. In women with low-normal TSH ≤2.5 μIU/mL,
TPO antibodies negatively affect embryo quality. In
women with high-normal TSH levels, increasing TSH
levels, and possibly TPO antibodies, appear to impair
embryo quality. These results suggest that the negative
impact of thyroid autoimmunity becomes apparent, once
thyroid hormone function is optimized.
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